INS and myotonic dystrophy type 2: The treatment of DM2 is directed toward the reduction of hyperglycemia and HbA1c (≤7%), in order to prevent cardiovascular and other long term risks (Table 1) [1, 2, 5]; there is a wide range of drugs which can be used in order to reduce glycemia, being notable mechanisms such as improving insulin secretion and reducing insulin resistance of peripheral tissues, as the case of TZDs [1–5], which are drugs targeting the peroxisome proliferator-activated receptor gamma (PPARγ).